Can I Take Glutathione with Cialis (Tadalafil)?

How Tadalafil Is Processed in the Body

Tadalafil is metabolized primarily by cytochrome P450 3A4 (CYP3A4) in the liver and intestinal wall. Understanding this pathway is the starting point for any interaction analysis, because anything that blocks or accelerates CYP3A4 will directly change how much active tadalafil circulates.

CYP3A4 and What That Means for Drug Interactions

The FDA prescribing information for Cialis confirms that potent CYP3A4 inhibitors, such as ketoconazole 200 mg/day, increase tadalafil AUC by up to 107% [1]. Strong CYP3A4 inducers such as rifampin 600 mg/day reduce tadalafil AUC by 88% [1]. That degree of sensitivity means any co-administered substance with CYP3A4 activity deserves scrutiny.

Tadalafil's oral bioavailability is roughly 80%, and its mean half-life of 17.5 hours allows once-daily dosing at 2.5 to 5 mg for BPH and daily ED treatment, or 10 to 20 mg on-demand use [1]. Because the drug persists in plasma for nearly 36 hours post-dose, even a slow-onset CYP3A4 interaction has time to accumulate.

Tadalafil's Nitric Oxide Pathway

Tadalafil works by inhibiting phosphodiesterase type 5 (PDE5), which raises cyclic guanosine monophosphate (cGMP) inside smooth-muscle cells, amplifying the vasodilatory signal from nitric oxide [1]. This pathway is worth noting because glutathione is closely tied to nitric oxide biology, as discussed in the next section.

What Glutathione Actually Does

Glutathione (gamma-glutamyl-cysteinyl-glycine) is the body's most abundant intracellular antioxidant. It scavenges reactive oxygen species, regenerates vitamins C and E, and participates directly in nitric oxide metabolism by forming S-nitrosoglutathione (GSNO) [2].

Oral vs. Injectable Glutathione: Different Pharmacokinetic Profiles

Oral glutathione is poorly absorbed intact. A randomized crossover study (N=40) published in the European Journal of Nutrition showed that oral glutathione 250 mg/day for four weeks raised whole-blood glutathione by 17% vs. Placebo (P<0.001), but plasma peaks were modest and transit-dependent [3]. Most orally ingested glutathione is hydrolyzed in the gut lumen to its constituent amino acids before reaching the portal circulation [3].

Intravenous or intramuscular glutathione bypasses the gastrointestinal barrier entirely, producing plasma concentrations that may be 10 to 40 times higher than oral dosing. Injectable glutathione is widely used off-label for skin brightening and antioxidant infusion protocols at doses of 600 to 2,400 mg per session [4]. This pharmacokinetic difference matters when assessing interaction risk with tadalafil.

Glutathione and Nitric Oxide: The Relevant Biochemistry

S-nitrosoglutathione (GSNO) acts as a nitric oxide reservoir and donor in vascular tissue. A 2015 study in Free Radical Biology and Medicine demonstrated that exogenous glutathione can increase bioavailable nitric oxide in endothelial cells under oxidative stress conditions [2]. Because tadalafil amplifies the downstream effects of nitric oxide through PDE5 inhibition, supraphysiologic glutathione concentrations could theoretically add to vasodilation. The clinical significance of this additive effect in humans at standard supplement doses has not been formally quantified [2].

The Pharmacokinetic Interaction: Does Glutathione Affect CYP3A4?

This is the core clinical question. Tadalafil's safety profile hinges almost entirely on CYP3A4 activity, so whether glutathione modulates that enzyme determines interaction risk.

In Vitro and Animal Evidence

In vitro studies show that reduced glutathione (GSH) does not act as a CYP3A4 inhibitor at physiological concentrations. A review of cytochrome P450-glutathione conjugation published in Drug Metabolism and Disposition found that GSH participates mainly in phase II conjugation reactions, not direct CYP enzyme inhibition [5]. Glutathione S-transferases (GSTs) are the relevant enzymes, and they operate independently of CYP3A4 [5].

Animal data from a rat hepatocyte model published in Toxicology Letters found that exogenous GSH at supraphysiologic concentrations (10 mM, far above any human plasma level) modestly upregulated CYP3A1 (the rat homolog of human CYP3A4) expression by approximately 12%, an effect too small and too species-specific to translate into a clinical dose adjustment for humans [6].

Human Pharmacokinetic Data

No published randomized controlled trial has directly measured tadalafil plasma levels during concomitant glutathione supplementation in humans. The absence of direct evidence means clinicians currently rely on mechanistic reasoning: because glutathione does not meaningfully inhibit or induce CYP3A4 in human hepatocytes at achievable plasma concentrations, a pharmacokinetic interaction altering tadalafil AUC is not expected [5].

The FDA's Cialis prescribing label does not list glutathione as a known or suspected interaction [1]. The Natural Medicines Database classifies the glutathione-tadalafil combination as having insufficient evidence to rate the interaction, which is distinct from a positive interaction signal [7].

The Pharmacodynamic Interaction: Blood Pressure and Vasodilation

Even without a pharmacokinetic effect, two substances can interact pharmacodynamically if they work through overlapping physiological pathways.

Additive Vasodilation Risk

Tadalafil lowers systolic blood pressure by a mean of 8.4 mmHg in normotensive men taking 10 mg on-demand [1]. Nitrates are absolutely contraindicated with tadalafil because they act on the same nitric oxide-cGMP pathway and can cause severe hypotension [1].

Glutathione is not a nitrate. At oral doses of 250 to 1,000 mg/day, no published study has documented clinically meaningful blood-pressure reduction in healthy volunteers [3]. A small pilot trial (N=12) in hypertensive patients receiving IV glutathione 1,200 mg showed a transient 5 to 7 mmHg systolic reduction that resolved within two hours [8]. At face value, this additive effect is mild and likely inconsequential for most patients, but men using daily-dose tadalafil 5 mg who also receive high-dose IV glutathione infusions may want their blood pressure monitored during or after the infusion.

Endothelial Function Overlap

Both tadalafil and glutathione improve endothelial function, though through distinct mechanisms. Tadalafil's endothelial effects have been characterized in the TADALA-CAD trial, where tadalafil 5 mg daily for 12 weeks improved flow-mediated dilation by 2.3% above placebo in men with coronary artery disease (N=173, P<0.001) [9]. Glutathione supplementation showed a similar direction of effect on flow-mediated dilation in a 2015 crossover trial in smokers (N=20), with IV glutathione 1,000 mg improving brachial artery FMD vs. Saline control (P<0.05) [8]. Both acting simultaneously may produce mildly additive endothelial benefit, which is not considered harmful in this context.

Injectable Glutathione: A Separate Consideration

The IV glutathione market has grown substantially. Wellness clinics often administer 600 to 2,400 mg per infusion, sometimes weekly. This route carries risks that oral dosing does not, independent of any tadalafil interaction.

FDA Regulatory Status of IV Glutathione

The FDA has not approved any injectable glutathione product for skin whitening or general antioxidant therapy. In 2020, the FDA issued a warning about the risks of injectable skin-lightening products, including glutathione formulations, citing concerns about infection, embolism, and unvalidated purity [10]. This regulatory gap means injectable glutathione products vary widely in concentration, vehicle, and sterility.

Clinical Monitoring When Combining IV Glutathione with Tadalafil

For a patient on daily tadalafil 5 mg who receives a high-dose IV glutathione infusion, the practical approach includes:

• Sitting blood pressure checked before and 60 minutes after the infusion
• Holding the infusion if systolic BP is already <100 mmHg pre-treatment
• Awareness that the vasodilatory effect of tadalafil persists for up to 36 hours post-dose at standard on-demand doses [1]
• Avoiding same-session combination with other vasodilatory agents (alpha-blockers, antihypertensives) if possible

What the Guidelines and Databases Say

No major clinical guideline, including the American Urological Association's 2021 ED guideline or the Endocrine Society's testosterone/sexual medicine guidance, specifically addresses glutathione co-administration with PDE5 inhibitors [11]. The absence of a warning is not a green light, but it does reflect the low level of reported concern in clinical practice.

The American College of Clinical Pharmacy's interaction database and the Natural Medicines Database both list this combination under "insufficient evidence," meaning no interaction signal has been identified but clinical trial confirmation is lacking [7].

The European Medicines Agency label for Adcirca (tadalafil for pulmonary arterial hypertension) similarly contains no mention of antioxidant supplement interactions, reinforcing the low-priority classification of this combination [12].

Specific Populations Where Extra Caution Applies

Men with Cardiovascular Disease

Men with known ischemic heart disease or heart failure taking tadalafil already have a narrow blood-pressure safety margin. For these patients, adding high-dose IV glutathione could theoretically widen any hypotensive dip. The ACC/AHA 2023 guidance on stable coronary artery disease advises caution with any agent that further lowers blood pressure when PDE5 inhibitors are in use [13].

Men with Liver Disease

Both tadalafil and glutathione are processed hepatically. In Child-Pugh Class A or B hepatic impairment, tadalafil AUC increases by approximately 21 to 63% compared with healthy subjects [1]. Glutathione is produced in the liver and its exogenous supplementation has been studied in non-alcoholic fatty liver disease (NAFLD), with a 4-month trial (N=29) showing reduced alanine aminotransferase (ALT) by a mean of 27 IU/L vs. Placebo [14]. In patients with significant liver disease, the altered hepatic environment may change the pharmacokinetics of both compounds, warranting closer physician supervision.

Men Using Alpha-Blockers

Tadalafil combined with alpha-blockers such as tamsulosin can lower blood pressure by an additional 7 to 8 mmHg systolic [1]. Adding high-dose IV glutathione to this combination creates a three-way vasodilatory scenario. The FDA label mandates using the lowest tadalafil dose when initiating alpha-blocker therapy [1], and the same conservatism applies when adding any agent with vasodilatory potential.

Practical Guidance: Timing, Doses, and Communication with Your Prescriber

Oral Glutathione (250 to 1,000 mg/day)

At standard oral supplementation doses, no dose-separation window from tadalafil is required based on current evidence. The poor intestinal absorption of oral glutathione limits systemic exposure, and the pharmacokinetic interaction risk with CYP3A4 is not expected [3][5]. Men taking once-daily tadalafil 5 mg can continue oral glutathione supplementation without timing adjustments, provided they report any new symptoms of dizziness or hypotension to their prescriber.

IV or Injectable Glutathione (600 to 2,400 mg/infusion)

For men using on-demand tadalafil 10 to 20 mg, scheduling the glutathione infusion more than 36 hours after the last tadalafil dose removes the period of peak drug exposure and is a practical precaution. For men on daily tadalafil, continuous steady-state drug levels make timing separation impossible; blood pressure monitoring before and after infusion is the appropriate safeguard instead.

Tell your prescribing physician about all supplements, including glutathione, before starting tadalafil or before adding a new supplement to an existing tadalafil regimen. The AUA 2021 guideline on erectile dysfunction recommends that clinicians conduct a thorough medication and supplement review before initiating any PDE5 inhibitor [11].

When to Stop and Seek Evaluation

Stop the infusion and contact a provider if any of the following occur during or within two hours of an IV glutathione infusion combined with tadalafil use:

• Systolic blood pressure falls below 90 mmHg
• Dizziness, lightheadedness, or syncope
• Chest pain or palpitations
• Flushing beyond what tadalafil alone typically produces